Innovative translational research in leukemia is critically dependent on the availability of funding for pilotprojects. The Leukemia SPORE Developmental Research Program (DRP) will be a source of seed fundingwith the following goals: 1) encourage and explore innovative translational research ideas which focus onleukemia research; and 2) encourage successful researchers working in other fields to focus their expertisetoward the development of innovative translational projects in leukemia research. Both laboratory andclinical research projects are eligible for funding, provided that they are translational in nature. The purposeof the SPORE Developmental Research Program is to develop translational research projects that shouldresult in clinically-testable hypotheses aimed at improving prognosis for patients with leukemia. Support of$100,000 from the SPORE and $100,000 from matching institutional support as described in the letter ofInstitutional Commitment will provide a total of $200,000 per year available through the DevelopmentalResearch Program for approximately 4 to 5 projects (approximately $50,000 per project). Funding will beawarded for 1 year; with satisfactory review from the respective advisory committees and progress on theindividual projects' specific aims, the funding could be carried over for an additional year.The specific objectives of the Developmental Research Program are to:1. Publicize the availability of funds for pilot translational leukemia research studies. Identify throughthis mechanism innovative projects with significant potential for improving leukemia therapy andprognosis.2. Encourage collaborations of projects with scientists within the SPORE and outside the SPORE.3. Enhance the communication between the SPORE leaders and outside investigators to encouragethe development of innovative translational strategies in leukemia.4. Ensure program flexibility so that developmental projects that show promise can be: 1) funded fora second year; 2) encouraged to apply for peer-reviewed funding (i.e. R01); or 3) expanded tobecome full SPORE projects.Lay Description: Innovative translational research in leukemia is critically dependent on the availability offunding for pilot projects. The Leukemia SPORE Developmental Research Program will be a source of seedfunding with the following goals: 1) encourage and explore innovative translational research ideas whichfocus on leukemia research; and 2) encourage successful researchers working in other fields to focus theirexpertise toward the development of innovative translational projects in leukemia research

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100632-06
Application #
7468684
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2008-09-01
Budget End
2009-04-30
Support Year
6
Fiscal Year
2008
Total Cost
$92,643
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Good, Charly Ryan; Panjarian, Shoghag; Kelly, Andrew D et al. (2018) TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. Cancer Res 78:4126-4137
Choi, Sangbum; Kang, Sangwook; Huang, Xuelin (2018) Smoothed quantile regression analysis of competing risks. Biom J 60:934-946
Boddu, Prajwal; Kantarjian, Hagop; Garcia-Manero, Guillermo et al. (2018) The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59:790-802
Yang, Tian-Hui; St John, Lisa S; Garber, Haven R et al. (2018) Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201:1389-1399
Rivera-Del Valle, Nilsa; Cheng, Tiewei; Irwin, Mary E et al. (2018) Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81:483-495
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Zhang, Hanghang; Pandey, Somnath; Travers, Meghan et al. (2018) Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell 175:1244-1258.e26
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Fiorini, Elena; Santoni, Andrea; Colla, Simona (2018) Dysfunctional telomeres and hematological disorders. Differentiation 100:1-11
Cortes, Jorge; Perl, Alexander E; Döhner, Hartmut et al. (2018) Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 19:889-903

Showing the most recent 10 out of 487 publications